Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at United Therapeutics Corporation ("United Therapeutics" or the "Company") UTHR.
The investigation focuses on whether the Company and its executives violated federal securities laws. On July 27, 2017, the Company reported its second quarter 2017 financial results in which it revealed an accrual of $210 million relating to settlement negotiations with the U.S. Department of Justice ("DOJ"). Specifically, the negotiations regard a DOJ investigation into whether the Company violated the Federal Anti-Kickback Statute and the Federal False Claims Act by supporting certain 501(c)(3) organizations that provide financial assistance to patients.
Following this disclosure, the Company's share price declined, causing harm to investors.
If you invested in United Therapeutics stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/UTHR. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170731006223/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
